Phase 2 trial with imeglimin in patients with Type 2 diabetes indicates effects on insulin secretion and sensitivity

INTRODUCTION: The aim of the present study was to evaluate the effect of 18‐week monotherapy with imeglimin on glucose tolerance and on insulin secretion/sensitivity in type 2 diabetic (T2D) patients. METHODS: The study was an 18‐week, double‐blind clinical trial in T2D subjects previously treated w...

Descripción completa

Detalles Bibliográficos
Autores principales: Theurey, Pierre, Thang, Carole, Pirags, Valdis, Mari, Andrea, Pacini, Giovanni, Bolze, Sébastien, Hallakou‐Bozec, Sophie, Fouqueray, Pascale
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9659655/
https://www.ncbi.nlm.nih.gov/pubmed/36239048
http://dx.doi.org/10.1002/edm2.371

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9659655/
https://www.ncbi.nlm.nih.gov/pubmed/36239048
http://dx.doi.org/10.1002/edm2.371

Ejemplares similares